Skip to main content


Continuing Education (CME)

First Annual Conference on CNS Clinical Trials 

October 1-2, 2021

This activity is jointly provided by Global Education Group and the Society for Neuro-Oncology 

This activity is supported by an educational grant from Novocure, Inc.

Target Audience

Neuro-oncologist, medical oncologist, neurosurgeons, radiation oncologist, radiologist, physicians/scientists, clinical and laboratory trainees, allied health professionals, pharmacists, and other medical professionals with an interest in clinical trials.

Statement of Need/Program Overview
First Annual Conference on CNS Clinical Trials, Co-Sponsored by SNO and ASCO brings together outstanding leaders in the field of Clinical Trials. Building on the success of our previous Clinical Trials meetings, the goal of this annual conference is to provide a deeper dive into the area of Neuro-Oncology clinical trials to understand how we can make a more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.

This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of Neuro-Oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other Neuro-Oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, it will provide a forum that promotes collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS.  

Educational Objectives
After completing this activity, the participant should be better able to:

  • Explain the consensus treatment of glioblastoma from an overview of clinical trials vs standard of care on the outcomes of overall survival.
  • Identify strategies to integrate the inclusion and reporting of quality-of-life endpoints in clinical trials of cancer drugs.
  • Explain the clinical trial landscape for GBM as it pertains to optimally evaluating new therapies and biomarkers.
  • Describe the use of real-world evidence and external control arms in clinical trials for primary and metastatic cancers of the CNS.
  • Compare novel imaging platforms that assess both response assessment and differentiation of tumor vs treatment effect, and their potential therapeutic applications for patients with primary and metastatic cancers of the CNS.

Please click here for the list of Invited Speakers and Panelists.
Please click here for the list of Moderators.
Please click here for the list of Scientific Committee Chairs.

Program Agenda
Click here to view current program*.  
*Pre-recorded video abstract presentations and electronic posters do not have CME credit.

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and the Society for Neuro-Oncology. Global is accredited by the ACCME to provide continuing medical education for physicians. 

* This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation
Global Education Group designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].

Instructions to Receive Credit
In order to receive credit for this activity, the participant must attend the virtual sessions and complete the program evaluation. An individualized CME/CE evaluation link will be emailed to each participant a week from the Conference from "[email protected]" with the subject line "CME/CE Websurvey Link."

Deadline to claim CE Credit will be Friday, November 5th at 11:59pm ET.

System Requirements

Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader* 

MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh. 
*Required to view printable (PDF) version of the lesson.

Refund/Cancellation Policy
The deadline for cancellations with refund is Monday, September 20, 2021. Cancellations must be received in writing and a $25 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization. 

Payment must be received in full before access to the virtual meeting can be granted. Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category and may cancel your registration if it is determined otherwise. Following the cancelation deadline, SNO will refund registrations that are cancelled for administrative reasons only; for all other registrations, no refunds are possible.

Email all cancellation and transfer requests to Program Registrar Caroline Noor, [email protected].

Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated. 

For a disclosure list of all individuals in control of content for the program please, click here.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Society for Neuro-Oncology do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Click here to return to the SNO CNS Trials Conference homepage.